investorscraft@gmail.com

Intrinsic Value of Adaptimmune Therapeutics PLC (ADAP)

Previous Close$1.48
Intrinsic Value
Upside potential
Previous Close
$1.48

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-09-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %341.5NaN
Revenue, $27NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m191NaN
Operating income, $m-164NaN
EBITDA, $m-158NaN
Interest expense (income), $mNaN
Earnings before tax, $m-163NaN
Tax expense, $m2NaN
Net income, $m-165NaN

BALANCE SHEET

Cash and short-term investments, $m205NaN
Total assets, $m329NaN
Adjusted assets (=assets-cash), $m124NaN
Average production assets, $m43NaN
Working capital, $m191NaN
Total debt, $m23NaN
Total liabilities, $m247NaN
Total equity, $m82NaN
Debt-to-equity ratio0.282NaN
Adjusted equity ratio-0.965NaN

CASH FLOW

Net income, $m-165NaN
Depreciation, amort., depletion, $m6NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-142NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-29NaN
Free cash flow, $m-112NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m191
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount